Verily, Kyverna Therapeutics partner to advance cell therapy for autoimmune diseases
The primary objectives of the collaboration include the identification of novel biomarkers and the enhancement of clinical trial…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
08 Sep 23
The primary objectives of the collaboration include the identification of novel biomarkers and the enhancement of clinical trial…
08 Sep 23
The two-part, multicenter, open-label, first-in-human phase 1/2 trial will assess the safety and efficacy of DS-3939 in patients…
07 Sep 23
The new research alliance will help advance three programmes over the next three years, of which two programmes…
07 Sep 23
The funding will facilitate the progress of Nimbus Therapeutics' portfolio of development initiatives in the fields of immunology,…
07 Sep 23
With the transaction, Kriya now own Tramontane’s FGF21 assets, including the latter’s adeno-associated virus (AAV) vector programme, designed…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Sep 23
BMS will obtain exclusive rights to develop and commercialise obexelimab, a bifunctional, non-cytolytic, humanised monoclonal antibody, in territories…
06 Sep 23
Abacavir/dolutegravir/lamivudine is a fixed-dose combination that consists of a pair of nucleoside reverse transcriptase inhibitors (NRTIs) and integrase…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Sep 23
The funding will be used to develop advanced Diamond-II upgrade, including a new and brighter synchrotron machine, with…
05 Sep 23
The OS in the Phase 3 trial crossed the pre-specified efficacy limit at interim analysis and investigator-assessed progression-free…
04 Sep 23
The consent order agreement with FTC allows Amgen to complete its proposed $27.8bn acquisition of Horizon Therapeutics, while…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates